About GPO   |   Newsroom/Media   |   Congressional Relations   |   Inspector General   |   Careers   |   Contact   |   askGPO   |   Help  
 
Home   |   Customers   |   Vendors   |   Libraries  

The Electronic Code of Federal Regulations (e-CFR) is a regularly updated, unofficial editorial compilation of CFR material and Federal Register amendments produced by the National Archives and Records Administration's Office of the Federal Register (OFR) and the Government Printing Office.

Parallel Table of Authorities and Rules for the Code of Federal Regulations and the United States Code
Text | PDF

Find, review, and submit comments on Federal rules that are open for comment and published in the Federal Register using Regulations.gov.

Purchase individual CFR titles from the U.S. Government Online Bookstore.

Find issues of the CFR (including issues prior to 1996) at a local Federal depository library.

[1]
 
 

Electronic Code of Federal Regulations

blue pill

e-CFR Data is current as of October 30, 2014

Title 21Chapter ISubchapter DPart 316


TITLE 21—Food and Drugs

CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED)

SUBCHAPTER D—DRUGS FOR HUMAN USE

PART 316—ORPHAN DRUGS

rule

Subpart A—GENERAL PROVISIONS

§316.1
Scope of this part.
§316.2
Purpose.
§316.3
Definitions.
§316.4
Address for submissions.
rule

Subpart B—WRITTEN RECOMMENDATIONS FOR INVESTIGATIONS OF ORPHAN DRUGS

§316.10
Content and format of a request for written recommendations.
§316.12
Providing written recommendations.
§316.14
Refusal to provide written recommendations.
rule

Subpart C—DESIGNATION OF AN ORPHAN DRUG

§316.20
Content and format of a request for orphan-drug designation.
§316.21
Verification of orphan-drug status.
§316.22
Permanent-resident agent for foreign sponsor.
§316.23
Timing of requests for orphan-drug designation; designation of already approved drugs.
§316.24
Deficiency letters and granting orphan-drug designation.
§316.25
Refusal to grant orphan-drug designation.
§316.26
Amendment to orphan-drug designation.
§316.27
Change in ownership of orphan-drug designation.
§316.28
Publication of orphan-drug designations.
§316.29
Revocation of orphan-drug designation.
§316.30
Annual reports of holder of orphan-drug designation.
rule

Subpart D—ORPHAN-DRUG EXCLUSIVE APPROVAL

§316.31
Scope of orphan-drug exclusive approval.
§316.34
FDA recognition of exclusive approval.
§316.36
Insufficient quantities of orphan drugs.
rule

Subpart E—OPEN PROTOCOLS FOR INVESTIGATIONS

§316.40
Treatment use of a designated orphan drug.
rule

Subpart F—AVAILABILITY OF INFORMATION

§316.50
Guidance documents.
§316.52
Availability for public disclosure of data and information in requests and applications.


For questions or comments regarding e-CFR editorial content, features, or design, email ecfr@nara.gov.
For questions concerning e-CFR programming and delivery issues, email webteam@gpo.gov.